Icelandic Salmon (ISLAX) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
3 Nov, 2026Executive summary
Q3 harvest was 5,200 tonnes versus 3,800 tonnes in Q3 2025; operational EBIT improved to EUR 1.4m from a EUR 9.4m loss.
Improved biological performance, lower underlying costs and stronger price achievement supported results.
Financial highlights
Q3 operating income was EUR 40.1m versus EUR 25.1m; operational EBIT was EUR 1.4m versus a EUR 9.4m loss.
YTD operating income was EUR 107.0m versus EUR 60.6m; operational EBIT was a EUR 1.9m loss versus a EUR 20.7m loss.
Q3 EBITDA generated EUR 5.1m of positive cash flow; fair-value adjustments were EUR 0.2m, with limited earnings and equity impact.
YTD harvest was 14.4k tonnes versus 8.9k tonnes; production tax was EUR 4.4m versus EUR 2.8m.
Outlook and guidance
2026 harvest guidance is 20,000 tonnes, with 1,300 tonnes shifted to 2027; 2027 guidance is 18,000 tonnes, affected by biological challenges.
Q4 costs are projected below Q3, though stable QoQ is the conservative outlook given biological issues at one 2025-generation site.
2027 harvest is expected to be backloaded, with 35%–40% in H1; smolt releases are expected to rise by ~800,000 to nearly 6 million.
Higher feed prices are expected to slightly increase 2027 costs; annual contract share is expected at ~10%.
Existing licenses could support 26,000 tonnes, but further growth and investment depend on regulatory clarity and an acceptable tax regime.
Latest events from Icelandic Salmon
- Harvest, revenue, and EBIT improved, but regulatory risks and biological challenges persist.ISLAX
Q2 2026 - Q1 EBIT neared break-even as volumes rose, with stable 2026 outlook despite lower prices.ISLAX
Q1 2026 - Q4 2025 delivered improved results and a positive outlook, with 2026 volume guidance at 21,300 tonnes.ISLAX
Q4 2025 - Operational loss from high costs, but harvest growth and 2026 recovery expected.ISLAX
Q3 2025 - Operational losses and lower guidance amid biological, regulatory, and market challenges.ISLAX
Q2 2025 - Harvest and EBIT were low in Q3, but strong demand and higher volumes are expected in Q4.ISLAX
Q3 2024 - Biological setbacks drove Q2 and H1 losses, but new licenses and ASC certification support growth.ISLAX
Q2 2024 - Biological setbacks and weak prices drove a Q1 2025 loss, but 2025 guidance is unchanged.ISLAX
Q1 2025 - Stabilized Q4 operations, strong demand, and 2025 volume guidance at 15,000 tonnes.ISLAX
Q4 2024